Associacio Per la Recerca Oncológica Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2012
NCT01784978
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Alternative names

Associacio Per la Recerca Oncológica (APRO)

Active Ingredients

Drugs in Phase 2 Trials (2)

everolimus (zortress) (1 trial)

sunitinib (sutent) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Renal Cell (Phase 2)

Kidney Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2